Event Cardio 10-Q 15 Jul 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	May 31, 2016	Jul. 11, 2016
Document And Entity Information
Entity Registrant Name	Event Cardio Group Inc.
Entity Central Index Key	1,394,130
Document Type	10-Q
Document Period End Date	May 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		130,395,186
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,016

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - CAD	May 31, 2016	Aug. 31, 2015
Current Assets
Cash	CAD 71,248	CAD 32,427
Prepaid expenses	387,382	568,537
Financing costs, net		105,999
Total Current Assets	458,630	706,963
Investment in Medpac Asia Pacific Unit Trust	206,332
Prepaid expenses - non-current portion	245,278	392,516
Property and Equipment, net	305	1,214
Deposit on equipment purchase	250,000	150,000
Financing Costs, net	88,071
TOTAL ASSETS	1,248,616	1,250,693
Current Liabilities
Accounts payable	425,658	598,835
Due to related parties	41,708	55,864
Notes payable - related parties		549,502
Total Current Liabilities	467,366	1,204,201
Convertible Notes Payable - Related Parties	1,258,053	525,000
TOTAL LIABILITIES	1,725,419	1,729,201
Stockholders' Deficit
Preferred stock, $0.001 par value; 10,000,000 shares authorized; nil shares issued and outstanding at May 31, 2016 and 10,000,000 issued and outstanding at August 31, 2015		10,000
Common stock, 300,000,000 shares authorized at $0.001 par value, 135,895,856 shares issued and outstanding at May 31, 2016 and 109,460,321 issued and outstanding at August 31, 2015	135,894	109,460
Additional paid in capital	4,272,653	2,110,237
Equity instruments to be issued	56,451	168,950
Subscriptions receivable	(324,427)
Accumulated other comprehensive income	336,600	103,432
Accumulated deficit	(4,953,974)	(2,980,587)
TOTAL STOCKHOLDERS' DEFICIT	(476,803)	(478,508)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	CAD 1,248,616	CAD 1,250,693

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	May 31, 2016	Aug. 31, 2015
Statement of Financial Position [Abstract]
Preferred Stock Par Value	$ 0.001	$ 0.001
Preferred Stock Shares Authorized	10,000,000	10,000,000
Preferred Stock Shares Issued	10,000,000	10,000,000
Preferred Stock Shares Outstanding	10,000,000	10,000,000
Common Stock Par Value	$ 0.001	$ 0.001
Common Stock Shares Authorized	300,000,000	300,000,000
Common Stock Shares Issued	135,895,856	109,460,321
Common Stock Shares Outstanding	135,895,856	109,460,321

Statements of Operations (Unaud

Statements of Operations (Unaudited)	3 Months Ended				9 Months Ended
	May 31, 2016$ / shares	May 31, 2016CADshares	May 31, 2015$ / shares	May 31, 2015CADshares	May 31, 2016$ / shares	May 31, 2016CADshares	May 31, 2015$ / shares	May 31, 2015CADshares
Income Statement [Abstract]
Revenue
Operating Expenses
General and administrative		276,465		378,001		1,032,018		681,473
Research and development - related party		356,156		185,549		640,332		323,778
Research and development - other		11,969		56,111		116,079		132,981
Total Operating Expenses		644,590		619,661		1,788,429		1,138,232
Loss from Operations		(644,590)		(619,661)		(1,788,429)		(1,138,232)
Other Expenses
Interest expense - related parties		29,069		15,749		68,019		55,818
Interest expense - other				3,500		13,080		3,500
Amortization - loan costs		13,187		9,443		103,859		26,857
Loss before Income Tax Credit		(686,846)		(648,353)		(1,973,387)		(1,224,407)
Net Loss		(686,846)		(648,353)		(1,973,387)		(1,224,407)
Other Comprehensive Income
Foreign currency translation adjustment		(138,619)		(13,694)		233,168		62,827
Comprehensive Loss		CAD (825,465)		CAD (662,047)		CAD (1,740,219)		CAD (1,161,580)
Loss per Share:
Basic and Diluted loss per share | $ / shares	$ (0.005)		$ (0.007)		$ (0.016)		$ (0.013)
Weighted Average Number of Shares Outstanding Basic and Diluted | shares		134,259,353		98,720,647		122,500,433		92,065,904

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - CAD	9 Months Ended
	May 31, 2016	May 31, 2015
Cash Flows from Operating Activities
Net loss	CAD (1,973,387)	CAD (1,224,407)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of prepaid expenses	729,379	212,579
Warrants issued for research and development - related party	78,996
Depreciation of property and equipment	904	1,016
Amortization of financing costs	103,859	22,741
Stock based compensation	34,746	113,125
Income from investment in Medpac Asia Pacific Unit Trust	(6,332)
Changes in assets and liabilities:
Prepaid expenses	(31,083)	(141,099)
Accounts payable	(78,074)	217,925
Net cash used in operating activities	(1,140,992)	(798,120)
Cash Flows from Investing Activities
Deposit on equipment purchase	(100,000)
Purchase of property and equipment		(150,000)
Net cash used in investing activities	(100,000)	(150,000)
Cash Flows from Financing Activities
Repayments of due to related parties	(14,577)	(27,566)
Advances from related parties		14,434
Proceeds from notes payable - related parties	76,886	195,822
Proceeds from convertible notes payable		500,000
Proceeds from issuance of common shares	982,581	197,000
Proceeds received on equity instruments to be issued	16,451
Net cash provided by financing activities	1,061,341	879,690
Effect of exchange rate on cash	218,472	16,430
Increase (Decrease) in Cash	38,821	(52,000)
Cash, beginning of period	32,427	86,617
Cash, end of period	71,248	34,617
Non-Cash Supplemental Cash Flow Information:
Issuance of common shares and common share purchase warrants for services recorded as prepaid expenses	367,552
Issuance of common shares for investment in Medpac Asia Pacific Unit Trust	200,000
Issuance of convertible not payable - related party for notes payable - related parties, accrued interest and financing costs	671,351
Issuance of common share purchase warrants for financing costs	CAD 59,247

1. OVERVIEW

1. OVERVIEW	9 Months Ended
	May 31, 2016
Accounting Policies [Abstract]
1. OVERVIEW	1. OVERVIEW Description of Business Event Cardio Group Inc. ("the Company") was incorporated under the name Sunrise Holdings Limited on October 26, 2005 under the laws of Nevada and changed its name to Event Cardio Group Inc. on November 7, 2014. The Company is developing a cardiac monitoring device based on a wireless and leadless advanced cardiac monitor. Upon completion of the development the device will collect medical data and transmit it to physicians for diagnostic evaluation. The Company also has a license agreement to distribute a patented product in the use of breast disease detection. On September 8, 2014, the Company entered into a share exchange agreement with Event Cardio Canada Inc.'s (formerly known as 2340960 Ontario Inc.) shareholders whereby the Company acquired all of the issued and outstanding common shares of Event Cardio Canada Inc. (formerly known as 2340960 Ontario Inc.) in exchange for 79,500,000 common shares of the Company. Upon completion of this transaction, the shareholders of Event Cardio Canada Inc. (formerly known as 2340960 Ontario Inc.) held approximately 93.6% of voting control of the Company. This transaction, has been accounted for as a reverse merger with Event Cardio Canada Inc. (formerly known as 2340960 Ontario Inc.) being the accounting acquirer and the Company being the acquiree. In connection with this transaction, the Company changed its fiscal year end from September 30th to August 31st. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any revenue since inception, has incurred losses, and has an accumulated deficit of $4,953,974 as of May 31, 2016. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern. The continuation of the Company as a going concern is dependent upon financial support from its stockholders, the ability of the Company to obtain necessary equity financing to continue operations, successfully locating and negotiating with other business entities for potential acquisitions and/or acquiring new clients to generate revenues. There is no assurance that the Company will ever be profitable. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern. Basis of Presentation These financial statements include the accounts of the Company and its wholly owned subsidiaries Event Cardio Canada Inc. (formerly known as 2340960 Ontario Inc.) and EFIL Sub of ECG Inc. All inter-company accounts and transactions have been eliminated. The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of May 31, 2016 and the results of operations and cash flows for the periods presented. The results of operations for the three months and nine months ended May 31, 2016 are not necessarily indicative of the operating results for the full fiscal year or any future period. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the form 10-K filed with the SEC on December 14, 2015. The Company has elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements and does not present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.

2. SUMMARY OF SIGNIFICANT ACCOU

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	May 31, 2016
Accounting Policies [Abstract]
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates In preparing these financial statements in conformity with GAAP, management is required to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting years. Actual results could differ from those estimates. Fair Value Measurements ASC 820, “ Fair Value Measurements The estimated fair value of certain financial instruments, including cash and cash equivalents, and accounts payable are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short and long term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features are comparable to rates of returns for instruments of similar credit risk. Share Based Compensation The Company applies ASC 718 Share-Based Compensation and ASC 505 Equity to account for service provider share-based payments. In accordance with ASC 718 and ASC 505, the Company determines whether a share based payment should be classified and accounted for as a liability award or equity award. All grants of share-based payments to service providers are classified as equity awards and are recognized in the financial statements over the period in which the services are received based on the fair value determined as of the measurement date. Included in prepaid expenses on the accompanying balance sheet at May 31, 2016 and August 31, 2015 is the unamortized portion of share based payments for services to be rendered of $553,396 and $791,962 respectively. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash with high quality banking institutions. Income Taxes Under ASC 740, "Income Taxes", deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, the Company has established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets will not be realized. The Company files income tax returns in Canada and the United States with varying statutes of limitations. The Company's policy is to recognize interest expense and penalties related to income tax matters as a component of our provision for income taxes. Foreign Currency Translation The Company's reporting and functional currency is the U.S. dollar. The Company's Canadian operation's functional currency is the Canadian dollar. The Company's U.S. subsidiary's functional currency is the U.S. dollar. Transactions originating in Canadian dollars are translated to the functional currency of the US dollar as follows: using period end rates of exchange for assets and liabilities, average rates of exchange for the period of transactions for revenues and expenses and historical rates for equity. The financial statements of the Company's Canadian operations are translated from the functional currency of the Canadian dollar into the reporting currency of the United States dollar in accordance with ASC 830, Foreign Currency Matters, using period end rates of exchange for assets and liabilities, average rates of exchange for the period for revenues and expenses and historical rates for equity. Translation adjustments resulting from the process of translating the functional currency of Canadian dollar Canadian operation's financial statements into the reporting currency of U.S. dollar financial statements are included in determining comprehensive income. As of May 31, 2016 and August 31, 2015, the cumulative translation adjustment of $336,600 and $103,432 respectively was classified as accumulated other comprehensive income in the stockholders' deficit section of the balance sheet. For the periods ended May 31, 2016 and May 31, 2015, the foreign currency translation adjustment to accumulated other comprehensive income was $233,168 and $62,827 respectively. Comprehensive Loss Comprehensive loss is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, Accounting Standards Codification (ASC) 200, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. For the year presented, the Company's comprehensive loss includes net loss and foreign currency translation adjustments and is presented in the statement of comprehensive loss. Investments in non-consolidated subsidiaries Investments in non-consolidated entities are accounted for using the equity method or cost basis depending upon the level of ownership and/or the Company's ability to exercise significant influence over the operating and financial policies of the investee. When the equity method is used, investments are recorded at original cost and adjusted periodically to recognize the Company's proportionate share of the investees' net income or losses after the date of investment. When net losses from an investment accounted for under the equity method exceed its carrying amount, the investment balance is reduced to zero and additional losses are not provided for. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company's share of that net income exceeds the share of net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred. Research and Development Expenses All research and development costs are expensed as incurred. Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

3. INVESTMENT IN MEDPAC ASIA PA

3. INVESTMENT IN MEDPAC ASIA PACIFIC UNIT TRUST	9 Months Ended
	May 31, 2016
Notes to Financial Statements
3. INVESTMENT IN MEDPAC ASIA PACIFIC UNIT TRUST	3. INVESTMENT IN MEDPAC ASIA PACIFIC UNIT TRUST The Company, in exchange for 4,000,000 common shares, valued at $200,000, acquired, on December 16, 2015, 200,000 trust units of Medpac Asia Pacific Unit Trust ("the entity") representing approximately 32.86% of the entity's voting units and thus has significant influence over the entity. As such, it is accounted for using the equity method. The company's proportionate share of the entity's income is adjusted for any inter-entity transactions between the company and the entity, which in this case would be interest on the convertible note payable described in Note 5.

4. DUE TO RELATED PARTIES

4. DUE TO RELATED PARTIES	9 Months Ended
	May 31, 2016
Notes to Financial Statements
4. DUE TO RELATED PARTIES	4. DUE TO RELATED PARTIES The amounts due to related parties are non-interest bearing, with no fixed terms of repayment, are payable on demand and are unsecured. As of May 31, 2016 and August 31, 2015, the amounts of due to related parties are $41,708 and $55,864 respectively.

5. CONVERTIBLE NOTES PAYABLE-RE

5. CONVERTIBLE NOTES PAYABLE-RELATED PARTIES	9 Months Ended
	May 31, 2016
Debt Disclosure [Abstract]
5. CONVERTIBLE NOTES PAYABLE-RELATED PARTIES	5. CONVERTIBLE NOTES PAYABLE - RELATED PARTIES The company offered, pursuant to a Regulation S Subscription Agreement and Investment Representation dated February 3, 2015, up to $2,000,000 of 8% convertible notes with interest payable annually on January 31st. The holder upon written notice to the company may elect to have accrued but unpaid interest added to the principal amount of the note in lieu of payment of interest. The principal amount of the note is payable on January 31, 2018. The note, or any part thereof and any unpaid interest is convertible into common shares of the company at any time at the option of the holder at a conversion price of $0.15 per common share. The note may be prepaid at any time in full by the company upon ten days notice to the holder. As at May 31, 2016, $525,000 of the convertible notes payable have been issued as follows. Medpac Asia Pacific Unit Trust ("Medpac") for $500,000. In addition to the terms of the convertible note payable described above, if the note is prepaid by the company at any time prior to the maturity date, if the volume weighted average price of the common shares of the company for the ten trading days preceding the early repayment date is less than $0.15 per common share, then Medpac shall receive a number of common share purchase warrants sufficient to purchase up to 1% of the then outstanding number of common shares of the Company. Such common share purchase warrants once issued would be exercisable for a period of three years at an exercise price of $0.15 per common share, but may be exercised on a cashless basis in accordance with a specified formula. Medpac also received, for its services as part of the transaction noted above, a convertible note payable of $25,000 having terms and conditions identical to Medpac's other convertible note payable described above, except that the number of common share purchase warrants potentially issuable upon early payment of the note would be sufficient to only purchase up to 0.0005% of the then outstanding common shares of the company. At the time of Medpac's investment noted above, the Company agreed to enter into an exclusive Distribution Agreement with Medpac for the Company's BreastCare DTS™ BreastCare DTS™ As at May 31, 2016 and August 31, 2015, the Company has a convertible promissory note outstanding to 2399371 Ontario Inc., a company owned by an affiliate, for $960,300 Canadian ($733,053 US$) and $nil Canadian ($nil US$), respectively. The note bears interest at 12% per annum with principal and interest both payable on the maturity date of January 31, 2018. The principal amount of the note together with any accrued interest is convertible into shares of the common stock of the Company at a conversion price of $0.0873 Canadian. The note is secured by the common shares of Event Cardio Canada Inc. (formerly 2340960 Ontario Inc.) and a lien on all of the company's assets. This note was issued on February 10, 2016, in satisfaction of the following other notes payable - related parties, accrued interest and financing fees: a promissory note to 2399371 Ontario Inc., a company owned by an affiliate, for $583,000 Canadian ($419,424 US$) plus accrued interest on such note of $110,770 Canadian ($79,691 US$); a promissory note to 2399371 Ontario Inc., a company owned by an affiliate, for $64,500 Canadian ($48,496 US$) plus accrued interest on such note of $4,515 Canadian ($3,339 US$); a promissory note to 2399371 Ontario Inc., a company owned by an affiliate, for $91,499 Canadian ($65,827 US$), which was issued December 18, 2015 in satisfaction of a promissory note to 9058583 Canada Inc., a company owned by an affiliate, plus accrued interest on such note of $2,346 Canadian ($1,735 US$); a promissory note to 2399371 Ontario Inc., a company owned by an affiliate, for $75,000 Canadian issued December 18, 2015 ($54,030 US$) plus accrued interest on such note of $1,923 Canadian ($1,422 US$); plus financing fees of $26,746 Canadian ($19,242 US$). Commitments to issue 600,000 common shares valued at $43,200 and 600,000 common share purchase warrants valued at $42,750 related to the above extinguished notes payable - related parties have been cancelled. Accrued interest on convertible notes payable - related parties as at May 31, 2016 and August 31, 2015 was $67,492 and $14,000 respectively and is included in accounts payable.

6. STOCKHOLDERS' DEFICIT

6. STOCKHOLDERS' DEFICIT	9 Months Ended
	May 31, 2016
Equity [Abstract]
6. STOCKHOLDERS' DEFICIT	6. STOCKHOLDERS' DEFICIT Common Shares and Common Share Purchase Warrant Issuance On September 28, 2015, the Company issued 4,100,000 common shares for proceeds of $205,000. In conjunction with this common share offering the company also issued 520,000 common shares in respect of finders fees. On September 28, 2015, the Company issued 1,250,000 common shares in exchange for a service agreement for a fair value of $137,500. On November 3, 2015, the Company issued 750,000 common shares in exchange for a service agreement for a fair value of $75,000. On November 3, 2015, the Company issued 125,000 common shares in exchange for a service agreement for a fair value of $12,500. On January 16, 2016, the Company issued 4,000,000 common shares in exchange for the investment in Medpac Asia Pacific Unit Trust for a fair value of $200,000. On February 8, 2016, the Company cancelled 750,000 common shares with a par value of $750 and additional paid in capital amount of $16,280, that were issued on September 28, 2015 due to default under the service agreement. Common Shares and Common Share Purchase Warrant Issuance (Continued) On March 8, 2016, the Company issued 16,901,400 common shares in exchange for proceeds of $1,127,009. On March 24, 2016, the Company cancelled 1,412,619 common shares and 10,000,000 preferred shares owned the company's subsidiary Event Cardio Canada Inc. (formerly known as 2340960 Ontario Inc.) with a par value of $1,413 and $10,000 both added to additional paid up capital for a total of $11,413. On April 6, 2016, the Company issued 250,000 common shares in exchange for a service agreement for a fair value of $7,000. On April 26, 2016, the Company issued 701,754 common shares in satisfaction of an obligation related to a license agreement as described in Note 8. Common Share Purchase Warrants On February 12, 2016, the Company issued 13,750,000 common share purchase warrants for research and development, compensation and consulting services with a fair value of $271,176. As of May 31, 2016 there are 30,050,000 common share purchase warrants issued and outstanding. 2,200,000 common share purchase warrants allow the holder to purchase 1 common share of the company at an exercise price of $0.10 per warrant up to the expiration date of August 27, 2019. 4,100,000 common share purchase warrants allow the holder to purchase 1 common share of the company at an exercise price of $0.10 per warrant up to the expiration date of September 28, 2019. 2,000,000 common share purchase warrants allow the holder to purchase 1 share of the company at an exercise price of $0.03 per warrant up to the expiration date of February 28, 2019. 11,750,000 common share purchase warrants allow the holder to purchase 1 share of the company at an exercise price of $0.01 per warrant up to the expiration date of February 28, 2019. 10,000,000 common share purchase warrants allow the holder to purchase 1 share of the company at an excise price of $0.15 per warrant up to the expiration date of February 28, 2019. Equity Instruments to be Issued The company has received $56,451 related to subscriptions for 1,050,000 common shares to be issued in the future. Equity Incentive Plan The Company has created the Event Cardio Group Inc. 2015 Equity Incentive Plan ("equity incentive plan") which allows for the Stock Options As of May 31, 2016 there are 500,000 stock options outstanding, allowing the holder to purchase one share of the common stock of the company company per option, at an exercise price of $0.15 per option up to the expiration date of December 31, 2019.

7. RELATED PARTIES

7. RELATED PARTIES	9 Months Ended
	May 31, 2016
Related Party Transactions [Abstract]
7. RELATED PARTIES	7. RELATED PARTIES The Company is related to Contex International Technologies (Canada) Inc. ("Contex") through the fact that affiliates of the Company hold a 34% interest in 2419596 Ontario Inc, which owns Contex. The Company has entered into a service agreement with Contex, whereby Contex will provide services related to the design and development of a wireless and leadless ECG cardiac monitor. The agreement runs for a term of one year to May 22, 2016 and will automatically renew for subsequent terms of one year unless notice of termination is given by either party in writing. For the nine months ended May 31, 2016 and May 31, 2015 $640,332 and $323,778 respectively, have been incurred related to this agreement and have been expensed in research and development expense. See Note 5 regarding convertible notes payable - related parties. The company is party to an employment agreement running from February 1, 2016 to January 31, 2018 with the CEO for $100,000 per year up to January 31, 2017, at which time the board will determine the annual salary for the second year. In addition, the CEO will be entitled to receive a bonus of $225,000 when the company achieves profitable operations. If the company is sold before the bonus has been paid in full, the CEO will be paid such amount out of the proceeds of the sale or cash on hand in the event of a stock sale. This employment agreement supercedes and replaces all obligations of the company under a previous employment agreement, dated August 27, 2015, with the CEO, whereby the CEO was to have earned a salary of $225,000 per year up to August 31, 2018 and was to have been paid $125,000 for past services. For the nine months ended May 31, 2016 and May 31, 2015, $32,333 and $nil respectively, have been expensed related to compensation to the CEO and included in general and administrative expense.

8. COMMITMENTS

8. COMMITMENTS	9 Months Ended
	May 31, 2016
Commitments and Contingencies Disclosure [Abstract]
8. COMMITMENTS	8. COMMITMENTS On October 24, 2014, the Company entered into a License Agreement with Life Medical Technologies, Inc. ('Life Medical") with respect to Life Medical’s “ BreastCare DTS™ BreastCare DTS™ As part of entering into the License Agreement, the Company has made prepayments of the royalties commitment noted above and such are included in prepaid expenses on the accompanying balance sheet at May 31, 2016. For the nine months ended May 31, 2016, and May 31, 2015 $116,667 and $nil respectively of the above noted prepayment has been expensed. The Company is party to a Sublicense agreement with 9508583 Canada Inc. with respect to the exclusive rights to distribute the BreastCare DTS™

9. CONTINGENCIES

9. CONTINGENCIES	9 Months Ended
	May 31, 2016
Commitments and Contingencies Disclosure [Abstract]
9. CONTINGENCIES	9. CONTINGENCIES On November 30, 2015, the company's subsidiary EFIL Sub of ECG Inc. received a breach of contract notice related to its license agreement with Life Medical as described in Note 8. Life Medical contends that the company has defaulted under the provisions of this agreement and have thus triggered penalty clauses in the agreement. Life Medical is now demanding payment of these penalties. As per the breach of contract notice details, it is estimated that the total penalty could be as high as $770,000 based on the formula: $1 per every 100 people in each designated country, up to a maximum of $150,000 per designated country, with a total of seven countries identified in the notice. In addition due to this breach, Life Medical also contends that the license rights to the seven countries identified now belongs exclusively to Life Medical. It is management's contention that the company has not defaulted under the provisions of the agreement and thus is not required to pay any such penalties, nor have the licensing rights reverted back to Life Medical in the seven countries identified. The outcome of this contingency is not determinable at this time.

10. SUBSEQUENT EVENTS

10. SUBSEQUENT EVENTS	9 Months Ended
	May 31, 2016
Subsequent Events [Abstract]
10. SUBSEQUENT EVENTS	10. SUBSEQUENT EVENTS Subscription Agreements On June 15, 2016, the Company sold 10,000,000 shares of common stock and warrants to purchase 5,000,000 shares of common stock for a purchase price of $1,000,000. The warrants may be exercised any time prior to May 26, 2019 at an initial exercise price of $0.25 per share. On June 16, 2016, the Company sold 2,500,000 shares of common stock and warrants to purchase 833,333 shares of common stock for a purchase price of $375,000. The warrants may be exercised any time prior to December 31, 2018 at an initial exercise price of $0.25 per share. Share Purchase and Option Agreement On June 16, 2016, the Company, entered into and consummated the transactions contemplated by a share purchase and option agreement with an affiliate and a shareholder. Pursuant to the agreement, the affiliate agreed to relinquish all rights under a license granted by the company in 2014 to market and distribute the Company's wireless cardiac monitoring device in Canada, including the right to exclusively market and distribute within the province of Ontario; the shareholder agreed to the repayment of the due to related party amount noted on the balance sheet at May 31, 2016 of $41,708 and the affiliate and the shareholder agreed to the release of all claims against the company. Further in pursuant to the agreement, the Company agreed to re-purchase for cancellation 20,000,000 shares of the company's common stock from a shareholder. Further in pursuant to the agreement, the company agreed to purchase 375 common shares of an affiliated entity 2419596 Ontario Inc., representing 37.5% of the ownership of that company. In addition the shareholder granted the company the option to purchase all, but not less than all of its remaining 9,812,500 shares of the Company's common stock owned for a price of $500,000 US exercisable at any time by the company prior to May 6, 2018. In exchange for all of the rights acquired and releases noted above, the company paid $1,024,949 Canadian (approximately $850,000 US), to be allocated as follows: $36,889 Cdn and the Cdn equivalent on $13,548 US in consideration of the due to related party amount of $41,708 US noted on the balance sheet at May 31, 2016; $37.50 Cdn in respect of the 375 common shares of 2419596 Ontario Inc. purchased, with the remainder being in respect of the 20,000,000 common shares of the company being repurchased for cancellation. Share Purchase Agreements On June 24, 2016, the company entered into, and consummated a share exchange agreement with two shareholders who are the shareholders of 100% of the capital stock of 2375757 Ontario Inc. Pursuant to this agreement, the company has acquired all of the outstanding shares of 2375757 Ontario Inc. for 2,812,500 shares of the company's common stock. 2375757 Ontario Inc. had previously acquired from the company's CEO's rights granted to him by the company in 2014 to market and distribute the company's wireless cardiac monitoring device in Canada. This transaction coupled with the share purchase and option agreement noted above now returns 100% of the rights to market and distribute the company's wireless cardiac monitoring device in Canada to the company. On June 30, 2016, the company entered into a stock purchase agreement, which closed July 8, 2016, to acquire 100% of the outstanding shares of Ambumed, Inc. and 100% of the membership interests in Capital Cardiac, LLC for consideration of $1,200,000 payable $600,000 upon closing and $600,000 payable on the first anniversary of closing, together with 2,000,000 restricted shares of the company's common stock, of which 500,000 shares will be deposited in escrow to satisfy the indemnification obligations of the former shareholders of Ambumed. The number of shares issued to the former shareholders of Ambumed is subject to adjustment if the market price of the common stock for the ten trading days preceding August 1, 2017 is less than $0.25 per share, the company will pay to one of the former shareholders of Ambumed, Inc. an amount equal to the product of (i) 1,000,000 and (ii) the excess of $0.25 over the market price. At the option of the company, it may pay any deficiency by the delivery of the number of shares times the market price equal to the amount due. As additional consideration, any and all automobiles of Ambumed, Inc. shall be transferred to a former shareholder of Ambumed, Inc. In addition, immediately prior to closing, Ambumed, Inc. shall distribute to its former shareholders, all cash and cash equivalents held by Ambumed, Inc.

1. OVERVIEW (Policies)

1. OVERVIEW (Policies)	9 Months Ended
	May 31, 2016
Accounting Policies [Abstract]
Description of Business	10. SUBSEQUENT EVENTS Subscription Agreements On June 15, 2016, the Company sold 10,000,000 shares of common stock and warrants to purchase 5,000,000 shares of common stock for a purchase price of $1,000,000. The warrants may be exercised any time prior to May 26, 2019 at an initial exercise price of $0.25 per share. On June 16, 2016, the Company sold 2,500,000 shares of common stock and warrants to purchase 833,333 shares of common stock for a purchase price of $375,000. The warrants may be exercised any time prior to December 31, 2018 at an initial exercise price of $0.25 per share. Share Purchase and Option Agreement On June 16, 2016, the Company, entered into and consummated the transactions contemplated by a share purchase and option agreement with an affiliate and a shareholder. Pursuant to the agreement, the affiliate agreed to relinquish all rights under a license granted by the company in 2014 to market and distribute the Company's wireless cardiac monitoring device in Canada, including the right to exclusively market and distribute within the province of Ontario; the shareholder agreed to the repayment of the due to related party amount noted on the balance sheet at May 31, 2016 of $41,708 and the affiliate and the shareholder agreed to the release of all claims against the company. Further in pursuant to the agreement, the Company agreed to re-purchase for cancellation 20,000,000 shares of the company's common stock from a shareholder. Further in pursuant to the agreement, the company agreed to purchase 375 common shares of an affiliated entity 2419596 Ontario Inc., representing 37.5% of the ownership of that company. In addition the shareholder granted the company the option to purchase all, but not less than all of its remaining 9,812,500 shares of the Company's common stock owned for a price of $500,000 US exercisable at any time by the company prior to May 6, 2018. In exchange for all of the rights acquired and releases noted above, the company paid $1,024,949 Canadian (approximately $850,000 US), to be allocated as follows: $36,889 Cdn and the Cdn equivalent on $13,548 US in consideration of the due to related party amount of $41,708 US noted on the balance sheet at May 31, 2016; $37.50 Cdn in respect of the 375 common shares of 2419596 Ontario Inc. purchased, with the remainder being in respect of the 20,000,000 common shares of the company being repurchased for cancellation. Share Purchase Agreements On June 24, 2016, the company entered into, and consummated a share exchange agreement with two shareholders who are the shareholders of 100% of the capital stock of 2375757 Ontario Inc. Pursuant to this agreement, the company has acquired all of the outstanding shares of 2375757 Ontario Inc. for 2,812,500 shares of the company's common stock. 2375757 Ontario Inc. had previously acquired from the company's CEO's rights granted to him by the company in 2014 to market and distribute the company's wireless cardiac monitoring device in Canada. This transaction coupled with the share purchase and option agreement noted above now returns 100% of the rights to market and distribute the company's wireless cardiac monitoring device in Canada to the company. On June 30, 2016, the company entered into a stock purchase agreement, which closed July 8, 2016, to acquire 100% of the outstanding shares of Ambumed, Inc. and 100% of the membership interests in Capital Cardiac, LLC for consideration of $1,200,000 payable $600,000 upon closing and $600,000 payable on the first anniversary of closing, together with 2,000,000 restricted shares of the company's common stock, of which 500,000 shares will be deposited in escrow to satisfy the indemnification obligations of the former shareholders of Ambumed. The number of shares issued to the former shareholders of Ambumed is subject to adjustment if the market price of the common stock for the ten trading days preceding August 1, 2017 is less than $0.25 per share, the company will pay to one of the former shareholders of Ambumed, Inc. an amount equal to the product of (i) 1,000,000 and (ii) the excess of $0.25 over the market price. At the option of the company, it may pay any deficiency by the delivery of the number of shares times the market price equal to the amount due. As additional consideration, any and all automobiles of Ambumed, Inc. shall be transferred to a former shareholder of Ambumed, Inc. In addition, immediately prior to closing, Ambumed, Inc. shall distribute to its former shareholders, all cash and cash equivalents held by Ambumed, Inc.
Going Concern	Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any revenue since inception, has incurred losses, and has an accumulated deficit of $4,953,974 as of May 31, 2016. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern. The continuation of the Company as a going concern is dependent upon financial support from its stockholders, the ability of the Company to obtain necessary equity financing to continue operations, successfully locating and negotiating with other business entities for potential acquisitions and/or acquiring new clients to generate revenues. There is no assurance that the Company will ever be profitable. These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.
Basis of Presentation	Basis of Presentation These financial statements include the accounts of the Company and its wholly owned subsidiaries Event Cardio Canada Inc. (formerly known as 2340960 Ontario Inc.) and EFIL Sub of ECG Inc. All inter-company accounts and transactions have been eliminated. The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of May 31, 2016 and the results of operations and cash flows for the periods presented. The results of operations for the three months and nine months ended May 31, 2016 are not necessarily indicative of the operating results for the full fiscal year or any future period. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes thereto included in the form 10-K filed with the SEC on December 14, 2015. The Company has elected to adopt early application of Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements and does not present or disclose inception-to-date information and other remaining disclosure requirements of Topic 915.

2. SUMMARY OF SIGNIFICANT ACC17

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	May 31, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates In preparing these financial statements in conformity with GAAP, management is required to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amount of revenues and expenses during the reporting years. Actual results could differ from those estimates.
Fair Value Measurements	Fair Value Measurements ASC 820, “ Fair Value Measurements The estimated fair value of certain financial instruments, including cash and cash equivalents, and accounts payable are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short and long term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features are comparable to rates of returns for instruments of similar credit risk.
Share Based Compensation	Share Based Compensation The Company applies ASC 718 Share-Based Compensation and ASC 505 Equity to account for service provider share-based payments. In accordance with ASC 718 and ASC 505, the Company determines whether a share based payment should be classified and accounted for as a liability award or equity award. All grants of share-based payments to service providers are classified as equity awards and are recognized in the financial statements over the period in which the services are received based on the fair value determined as of the measurement date. Included in prepaid expenses on the accompanying balance sheet at May 31, 2016 and August 31, 2015 is the unamortized portion of share based payments for services to be rendered of $553,396 and $791,962 respectively.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash with high quality banking institutions.
Income Taxes	Income Taxes Under ASC 740, "Income Taxes", deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, the Company has established a full valuation allowance against all of the deferred tax assets for every period because it is more likely than not that all of the deferred tax assets will not be realized. The Company files income tax returns in Canada and the United States with varying statutes of limitations. The Company's policy is to recognize interest expense and penalties related to income tax matters as a component of our provision for income taxes.
Foreign Currency Translation	Foreign Currency Translation The Company's reporting and functional currency is the U.S. dollar. The Company's Canadian operation's functional currency is the Canadian dollar. The Company's U.S. subsidiary's functional currency is the U.S. dollar. Transactions originating in Canadian dollars are translated to the functional currency of the US dollar as follows: using period end rates of exchange for assets and liabilities, average rates of exchange for the period of transactions for revenues and expenses and historical rates for equity. The financial statements of the Company's Canadian operations are translated from the functional currency of the Canadian dollar into the reporting currency of the United States dollar in accordance with ASC 830, Foreign Currency Matters, using period end rates of exchange for assets and liabilities, average rates of exchange for the period for revenues and expenses and historical rates for equity. Translation adjustments resulting from the process of translating the functional currency of Canadian dollar Canadian operation's financial statements into the reporting currency of U.S. dollar financial statements are included in determining comprehensive income. As of May 31, 2016 and August 31, 2015, the cumulative translation adjustment of $336,600 and $103,432 respectively was classified as accumulated other comprehensive income in the stockholders' deficit section of the balance sheet. For the periods ended May 31, 2016 and May 31, 2015, the foreign currency translation adjustment to accumulated other comprehensive income was $233,168 and $62,827 respectively.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined to include all changes in equity except those resulting from investments by owners and distributions to owners. Among other disclosures, Accounting Standards Codification (ASC) 200, Comprehensive Income, requires that all items that are required to be recognized under current accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. For the year presented, the Company's comprehensive loss includes net loss and foreign currency translation adjustments and is presented in the statement of comprehensive loss.
Investment in non-consolidated subsidiaries	Investments in non-consolidated subsidiaries Investments in non-consolidated entities are accounted for using the equity method or cost basis depending upon the level of ownership and/or the Company's ability to exercise significant influence over the operating and financial policies of the investee. When the equity method is used, investments are recorded at original cost and adjusted periodically to recognize the Company's proportionate share of the investees' net income or losses after the date of investment. When net losses from an investment accounted for under the equity method exceed its carrying amount, the investment balance is reduced to zero and additional losses are not provided for. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company's share of that net income exceeds the share of net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred.
Research and Development Expenses	Research and Development Expenses All research and development costs are expensed as incurred.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: To record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the noted transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

1. OVERVIEW (Details Narrative)

1. OVERVIEW (Details Narrative) - CAD	May 31, 2016	Aug. 31, 2015
Accounting Policies [Abstract]
Accumulated Deficit	CAD (4,953,974)	CAD (2,980,587)

4. DUE TO RELATED PARTIES (Deta

4. DUE TO RELATED PARTIES (Details Narrative) - CAD	May 31, 2016	Aug. 31, 2015
Notes to Financial Statements
Due to Related Parties	CAD 41,708	CAD 55,864

7. RELATED PARTY (Details Narra

7. RELATED PARTY (Details Narrative) - CAD	9 Months Ended
	May 31, 2016	May 31, 2015
Research and Development Expense	CAD 640,332	CAD 323,778
Compensation to CEO	CAD 32,333	CAD 0
2419596 Ontario Inc.
Ownership Percentage	34.00%

8. COMMITMENTS (Details Narrati

8. COMMITMENTS (Details Narrative) - CAD	9 Months Ended
	May 31, 2016	May 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Prepayment of Royalties	CAD 116,667	CAD 116,667